Literature DB >> 14982803

In vitro activities of tigecycline against the Bacteroides fragilis group.

N V Jacobus1, L A McDermott, R Ruthazer, D R Snydman.   

Abstract

The in vitro activities of tigecycline were tested against 831 isolates of the Bacteroides fragilis group representing all of the species within the group. On a weight-to-weight basis (8 microg/ml), tigecycline was more active than clindamycin, minocycline, trovafloxacin, and cefoxitin and less active than imipenem or piperacillin-tazobactam against all isolates of the B. fragilis group. Tigecycline geometric mean MICs were statistically higher against B. distasonis than other Bacteroides species (P value of 0.0001).

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14982803      PMCID： PMC353084          DOI： 10.1128/AAC.48.3.1034-1036.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.

Authors:  A C Gales; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2000-01       Impact factor: 2.803

2.  In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline.

Authors:  C Edlund; C E Nord
Journal:  Clin Microbiol Infect       Date:  2000-03       Impact factor: 8.067

3.  Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.

Authors:  K E Aldridge; D Ashcraft; K Cambre; C L Pierson; S G Jenkins; J E Rosenblatt
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

4.  Comparative in vitro activities of clinafloxacin and trovafloxacin against 1,000 isolates of bacteroides fragilis group: effect of the medium on test results.

Authors:  D R Snydman; N V Jacobus; L A McDermott; S E Supran
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

5.  In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

Authors:  P J Petersen; N V Jacobus; W J Weiss; P E Sum; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

6.  In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.

Authors:  Carmen Betriu; Iciar Rodríguez-Avial; Blas Ali Sánchez; María Gómez; Juan Alvarez; Juan J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

7.  Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.

Authors:  D R Snydman; L McDermott; G J Cuchural; D W Hecht; P B Iannini; L J Harrell; S G Jenkins; J P O'Keefe; C L Pierson; J D Rihs; V L Yu; S M Finegold; S L Gorbach
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

8.  In vitro activities of newer quinolones against bacteroides group organisms.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; E Goldstein; S Finegold; L Harrell; D W Hecht; S Jenkins; C Pierson; R Venezia; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.

Authors:  Peter J Petersen; Patricia A Bradford; William J Weiss; Timothy M Murphy; P E Sum; Steven J Projan
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines.

Authors:  R T Testa; P J Petersen; N V Jacobus; P E Sum; V J Lee; F P Tally
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191
  10 in total
  13 in total

1.  Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 2.  Tigecycline.

Authors:  James E Frampton; Monique P Curran
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Antianaerobic antimicrobials: spectrum and susceptibility testing.

Authors:  Itzhak Brook; Hannah M Wexler; Ellie J C Goldstein
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

4.  Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.

Authors:  Carmen Betriu; Esther Culebras; María Gómez; Fátima López; Iciar Rodríguez-Avial; Juan J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

5.  In vitro activity of ten antibiotics, including tigecycline, against Bacteroides species in Austria.

Authors:  A J Grisold; I Wendelin; E Presterl; R B Raggam; L Masoud; A Badura; E Marth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-07       Impact factor: 3.267

6.  Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem.

Authors:  María Eugenia Pachón-Ibáñez; Manuel Enrique Jiménez-Mejías; Cristina Pichardo; Ana Cristina Llanos; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

Review 7.  Tigecycline: a novel glycylcycline.

Authors:  Ethan Rubinstein; David Vaughan
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method.

Authors:  Patricia A Bradford; Peter J Petersen; Mairead Young; C Hal Jones; Mark Tischler; John O'Connell
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

9.  Effect of tigecycline on normal oropharyngeal and intestinal microflora.

Authors:  Carl Erik Nord; Eva Sillerström; Elisabeth Wahlund
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

Review 10.  Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.

Authors:  Drosos E Karageorgopoulos; Theodore Kelesidis; Iosif Kelesidis; Matthew E Falagas
Journal:  J Antimicrob Chemother       Date:  2008-04-24       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.